Transcriptomic Changes Involved in the Dedifferentiation of Myofibroblasts Derived from the Lung of a Patient with Idiopathic Pulmonary Fibrosis

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2020 Jul 7

PMID 32626975

Citations 12

Authors

Kenichi Suzuki

Jun-Dal Kim

Keita Ugai

Shuichi Matsuda

Hideki Mikami

Kento Yoshioka

Jun Ikari

Masahiko Hatano

Akiyoshi Fukamizu

Koichiro Tatsumi

Yoshitoshi Kasuya

Affiliations

Soon will be listed here.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease of unknown etiology. Under pathological conditions in lungs with IPF, myofibroblasts serve a key role in fibrogenesis via the accumulation of an excessive amount of extracellular matrix. To develop effective therapeutic interventions against IPF, studies have recently focused on how to dedifferentiate established myofibroblasts. The present study revealed that JQ1, an inhibitor of bromodomain and extra‑terminal proteins, markedly suppressed the expression levels of α‑smooth muscle actin and ED‑A‑fibronectin in myofibroblasts prepared from the lung of a patient with end‑stage IPF. Furthermore, these findings were supported by transcriptome analysis using RNA sequencing, in which differentially expressed genes (DEGs) downregulated by JQ1 treatment were significantly enriched in the fibrosis‑related signaling pathway. On the other hand, the upregulated DEGs in response to JQ1 treatment were significantly enriched in glutathione metabolism, which may affect the cell status of fibroblast/myofibroblast. To the best of our knowledge, this was the first study to comprehensively analyze transcriptome profiles associated with dedifferentiation of IPF myofibroblasts.

Citing Articles

BRD4: an effective target for organ fibrosis.

Wei Q, Gan C, Sun M, Xie Y, Liu H, Xue T Biomark Res. 2024; 12(1):92.

PMID: 39215370 PMC: 11365212. DOI: 10.1186/s40364-024-00641-6.

Regulation of myofibroblast dedifferentiation in pulmonary fibrosis.

Ju X, Wang K, Wang C, Zeng C, Wang Y, Yu J Respir Res. 2024; 25(1):284.

PMID: 39026235 PMC: 11264880. DOI: 10.1186/s12931-024-02898-9.

MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution.

Fortier S, Walker N, Penke L, Baas J, Shen Q, Speth J J Clin Invest. 2024; 134(10).

PMID: 38512415 PMC: 11093610. DOI: 10.1172/JCI172826.

BRD4 as a Therapeutic Target in Pulmonary Diseases.

Guo X, Olajuyin A, Tucker T, Idell S, Qian G Int J Mol Sci. 2023; 24(17).

PMID: 37686037 PMC: 10487829. DOI: 10.3390/ijms241713231.

Functional roles of CD26/DPP4 in bleomycin-induced pulmonary fibrosis.

Koyanagi Y, Kawasaki T, Kasuya Y, Hatano R, Sato S, Takahashi Y Physiol Rep. 2023; 11(6):e15645.

PMID: 36949656 PMC: 10034007. DOI: 10.14814/phy2.15645.

References

Sieber P, Schafer A, Lieberherr R, Le Goff F, Stritt M, Welford R . Novel high-throughput myofibroblast assays identify agonists with therapeutic potential in pulmonary fibrosis that act via EP2 and EP4 receptors. PLoS One. 2018; 13(11):e0207872. PMC: 6261607. DOI: 10.1371/journal.pone.0207872. View

Lyu X, Fang W, Cai L, Zheng H, Ye Y, Zhang L . TGFβR2 is a major target of miR-93 in nasopharyngeal carcinoma aggressiveness. Mol Cancer. 2014; 13:51. PMC: 4016586. DOI: 10.1186/1476-4598-13-51. View

Huang S, Fisher A, Scruggs A, White E, Hogaboam C, Richardson B . Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. Am J Pathol. 2010; 177(5):2245-55. PMC: 2966784. DOI: 10.2353/ajpath.2010.100446. View

Christmann R, Wooten A, Sampaio-Barros P, Borges C, Carvalho C, Kairalla R . miR-155 in the progression of lung fibrosis in systemic sclerosis. Arthritis Res Ther. 2016; 18(1):155. PMC: 4932708. DOI: 10.1186/s13075-016-1054-6. View

Oak S, Murray L, Herath A, Sleeman M, Anderson I, Joshi A . A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis. PLoS One. 2011; 6(6):e21253. PMC: 3119674. DOI: 10.1371/journal.pone.0021253. View

Pierce E, Carpenter K, Jakubzick C, Kunkel S, Flaherty K, Martinez F . Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice. Am J Pathol. 2007; 170(4):1152-64. PMC: 1829450. DOI: 10.2353/ajpath.2007.060649. View

Tang X, Peng R, Phillips J, Deguzman J, Ren Y, Apparsundaram S . Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis. Am J Pathol. 2013; 183(2):470-9. DOI: 10.1016/j.ajpath.2013.04.020. View

Ohkuro M, Kim J, Kuboi Y, Hayashi Y, Mizukami H, Kobayashi-Kuramochi H . Calreticulin and integrin alpha dissociation induces anti-inflammatory programming in animal models of inflammatory bowel disease. Nat Commun. 2018; 9(1):1982. PMC: 5958137. DOI: 10.1038/s41467-018-04420-4. View

Kendall R, Feghali-Bostwick C . Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014; 5:123. PMC: 4034148. DOI: 10.3389/fphar.2014.00123. View

10.

Sanders Y, Ambalavanan N, Halloran B, Zhang X, Liu H, Crossman D . Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 186(6):525-35. PMC: 3480526. DOI: 10.1164/rccm.201201-0077OC. View

11.

King Jr T, Schwarz M, Brown K, Tooze J, Colby T, Waldron Jr J . Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001; 164(6):1025-32. DOI: 10.1164/ajrccm.164.6.2001056. View

12.

Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal V . miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010; 207(8):1589-97. PMC: 2916139. DOI: 10.1084/jem.20100035. View

13.

Yamazaki R, Kasuya Y, Fujita T, Umezawa H, Yanagihara M, Nakamura H . Antifibrotic effects of cyclosporine A on TGF-β1-treated lung fibroblasts and lungs from bleomycin-treated mice: role of hypoxia-inducible factor-1α. FASEB J. 2017; 31(8):3359-3371. DOI: 10.1096/fj.201601357R. View

14.

Davies E, Haitchi H, Thatcher T, Sime P, Kottmann R, Ganesan A . Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012; 46(5):687-94. PMC: 4854311. DOI: 10.1165/rcmb.2011-0040OC. View

15.

Raghu G, Noth I, Martinez F . N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open. Lancet Respir Med. 2016; 5(1):e1-e2. DOI: 10.1016/S2213-2600(16)30327-7. View

16.

Hunninghake G . Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med. 2005; 353(21):2285-7. DOI: 10.1056/NEJMe058210. View

17.

Lederer D, Martinez F . Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018; 378(19):1811-1823. DOI: 10.1056/NEJMra1705751. View

18.

Gong Y, Wang N, Liu N, Dong H . Lipid Peroxidation and GPX4 Inhibition Are Common Causes for Myofibroblast Differentiation and Ferroptosis. DNA Cell Biol. 2019; 38(7):725-733. DOI: 10.1089/dna.2018.4541. View

19.

Wynes M, Edelman B, Kostyk A, Edwards M, Coldren C, Groshong S . Increased cell surface Fas expression is necessary and sufficient to sensitize lung fibroblasts to Fas ligation-induced apoptosis: implications for fibroblast accumulation in idiopathic pulmonary fibrosis. J Immunol. 2011; 187(1):527-37. DOI: 10.4049/jimmunol.1100447. View

20.

Anathy V, Roberson E, Guala A, Godburn K, Budd R, Janssen-Heininger Y . Redox-based regulation of apoptosis: S-glutathionylation as a regulatory mechanism to control cell death. Antioxid Redox Signal. 2011; 16(6):496-505. PMC: 3304251. DOI: 10.1089/ars.2011.4281. View